Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 126

1.

Functional properties of the HIV-1 long terminal repeat containing single-nucleotide polymorphisms in Sp site III and CCAAT/enhancer binding protein site I.

Shah S, Alexaki A, Pirrone V, Dahiya S, Nonnemacher MR, Wigdahl B.

Virol J. 2014 May 16;11:92. doi: 10.1186/1743-422X-11-92.

3.

Analysis of the HIV-1 LTR NF-kappaB-proximal Sp site III: evidence for cell type-specific gene regulation and viral replication.

McAllister JJ, Phillips D, Millhouse S, Conner J, Hogan T, Ross HL, Wigdahl B.

Virology. 2000 Sep 1;274(2):262-77.

4.

Impact of viral activators and epigenetic regulators on HIV-1 LTRs containing naturally occurring single nucleotide polymorphisms.

Shah S, Pirrone V, Alexaki A, Nonnemacher MR, Wigdahl B.

Biomed Res Int. 2015;2015:320642. doi: 10.1155/2015/320642. Epub 2015 Jan 5.

6.
7.

Sp1 and related factors fail to interact with the NF-kappaB-proximal G/C box in the LTR of a replication competent, brain-derived strain of HIV-1 (YU-2).

Millhouse S, Krebs FC, Yao J, McAllister JJ, Conner J, Ross H, Wigdahl B.

J Neurovirol. 1998 Jun;4(3):312-23.

PMID:
9639074
8.

C/EBP- and Tat-mediated activation of the HIV-1 LTR in CD34+ hematopoietic progenitor cells.

Quiterio S, Grant C, Hogan TH, Krebs FC, Wigdahl B.

Biomed Pharmacother. 2003 Jan;57(1):49-56.

PMID:
12642037
9.

HIV-1 Vpr binding to HIV-1 LTR C/EBP cis-acting elements and adjacent regions is sequence-specific.

Hogan TH, Nonnemacher MR, Krebs FC, Henderson A, Wigdahl B.

Biomed Pharmacother. 2003 Jan;57(1):41-8.

PMID:
12642036
10.

CCAAT enhancer binding protein and nuclear factor of activated T cells regulate HIV-1 LTR via a novel conserved downstream site in cells of the monocyte-macrophage lineage.

Dahiya S, Liu Y, Nonnemacher MR, Dampier W, Wigdahl B.

PLoS One. 2014 Feb 14;9(2):e88116. doi: 10.1371/journal.pone.0088116. eCollection 2014.

12.
13.

Development of co-selected single nucleotide polymorphisms in the viral promoter precedes the onset of human immunodeficiency virus type 1-associated neurocognitive impairment.

Li L, Aiamkitsumrit B, Pirrone V, Nonnemacher MR, Wojno A, Passic S, Flaig K, Kilareski E, Blakey B, Ku J, Parikh N, Shah R, Martin-Garcia J, Moldover B, Servance L, Downie D, Lewis S, Jacobson JM, Kolson D, Wigdahl B.

J Neurovirol. 2011 Feb;17(1):92-109. doi: 10.1007/s13365-010-0014-1. Epub 2011 Jan 12.

15.

Structural and functional studies of CCAAT/enhancer binding sites within the human immunodeficiency virus type 1 subtype C LTR.

Liu Y, Nonnemacher MR, Stauff DL, Li L, Banerjee A, Irish B, Kilareski E, Rajagopalan N, Suchitra JB, Khan ZK, Ranga U, Wigdahl B.

Biomed Pharmacother. 2010 Dec;64(10):672-80. doi: 10.1016/j.biopha.2010.09.007. Epub 2010 Sep 25.

16.

HIV-1 LTR C/EBP binding site sequence configurations preferentially encountered in brain lead to enhanced C/EBP factor binding and increased LTR-specific activity.

Ross HL, Gartner S, McArthur JC, Corboy JR, McAllister JJ, Millhouse S, Wigdahl B.

J Neurovirol. 2001 Jun;7(3):235-49.

PMID:
11517398
17.
18.

T-cell activation leads to poor activation of the HIV-1 clade E long terminal repeat and weak association of nuclear factor-kappaB and NFAT with its enhancer region.

Lemieux AM, Paré ME, Audet B, Legault E, Lefort S, Boucher N, Landry S, van Opijnen T, Berkhout B, Naghavi MH, Tremblay MJ, Barbeau B.

J Biol Chem. 2004 Dec 17;279(51):52949-60. Epub 2004 Oct 1.

19.

Identification of binding sites for members of the CCAAT/enhancer binding protein transcription factor family in the simian immunodeficiency virus long terminal repeat.

Nonnemacher MR, Hogan TH, Quiterio S, Wigdahl B, Henderson A, Krebs FC.

Biomed Pharmacother. 2003 Jan;57(1):34-40.

PMID:
12642035
20.

Functional differences between the long terminal repeat transcriptional promoters of human immunodeficiency virus type 1 subtypes A through G.

Jeeninga RE, Hoogenkamp M, Armand-Ugon M, de Baar M, Verhoef K, Berkhout B.

J Virol. 2000 Apr;74(8):3740-51.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk